Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): Assessment of joint mobility and grip and pinch strength

Jornal de Pediatria

Volumn 84, Issue 2, 2008, Pages 130-135

  Cardoso Santos, Antonio ^a,b   Azevedo, Ana C M M ^b   Fagondes, Simone ^b   Burin, Maira G ^b   Giugliani, Roberto ^a   Schwartz, Ida V D ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UFRGS ^*

Author keywords

Joint mobility; Mucopolysaccharidosis type VI; Muscle strength

Indexed keywords

GLYCOSAMINOGLYCAN; N ACETYLGALACTOSAMINE 4 SULFATASE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ELBOW FLEXION; ENZYME ACTIVITY; ENZYME REPLACEMENT; FEMALE; GRIP STRENGTH; HAND GRIP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JOINT MOBILITY; MALE; MAROTEAUX LAMY SYNDROME; MUSCLE STRENGTH; PINCH STRENGTH; SCORING SYSTEM; URINARY EXCRETION; WALKING;

CHILD; ELBOW JOINT; FEMALE; GLYCOSAMINOGLYCANS; HAND STRENGTH; HUMANS; JOINT INSTABILITY; KNEE JOINT; MALE; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; REFERENCE VALUES; SHOULDER JOINT;

EID: 43049090500     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1743     Document Type: Article

References (24)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-54.
2. Neufeld E, Muenzer J. The mucopolysacharidoses. In: Scriver C, Beandet A, Sly S, Valle D, Childs B, Kinzler K, et al., editors. The metabolic and molecular basis of inherited diseases. 8th ed. New York: McGraw-Hill; 2001. p. 3421 52.
3. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, vanWeely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151-6.
4. Pinto LL, Schwartz IV, Puga AC, Vieira TA, Munoz MV, Giugliani R. Prospective study of 11 Brazilian patients with mucipolysaccharidosis II. J Pediatr (Rio J). 2006;82:273-8.
5. Azevedo AC, Schwartz IV, Kalakun L, Brustolin S, Burin MG, Beheregaray AP, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet. 2004;66:208-13.
6. Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl. 2007;96:63-70.
7. Nyhan W, Ozand P. Maratoux-Lamy disease Mucopolysaccharidoses VI (MPS VI) / N-Acetylgalactosamine-4-sulfatase deficiency. In: Nyhan W, Ozand P, editors. Atlas of metabolic diseases. London: Chapman & Hall; 1998. p. 477 81.
8. Azevedo AC Estudo clínico e bioquímico de 28 pacientes com mucopolissacaridose tipo VI [dissertação]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2004.
9. Coelho JC, Wajner M, Burin MG, Vargas CR, Giugliani R. Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur J Pediatr. 1997;156:650-4.
10. Schwartz I, Matte U, Leistner S, Giugliani R. Mucopolissacaridoses. In: Carakushanski G, editor. Doenças genéticas em pediatria. Rio de Janeiro: Guanabara Koogan; 2001. p. 180 4.
11. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681-9.
12. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533-9.
13. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzymereplacement therapy for 6 years.Mol Genet Metab. 2007;90:171-80.
14. Cox-Brinkman J, Smeulders MJ, Hollak CE, Wijburg FA. Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J Inherit Metab Dis. 2007;30:47-50.
15. Gajdosik RL, Bohannon RW. Clinical measurement of range of motion. Review of goniometry emphasizing reliability and validity. Phys Ther. 1987;67:1867-72.
16. Riddle DL, Rothstein JM, Lamb RL. Goniometric reliability in a clinical setting. Shoulder measurements. Phys Ther. 1987;67:668-73.
17. de Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem. 1992;38:803-7.
18. Kresse H, von Figura K, Klein U, Glossl J, Paschke E, Pohlmann R. Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol. 1982;83:559-72.
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-7.
20. Delisa JA. Medicina de reabilitação: princípios e práticas. São Paulo: Manole; 1992.
21. Mathiowetz V, Wiemer DM, Federman SM. Grip and pinch strength: norms for 6- to 19-year-olds. Am J Occup Ther. 1986;40:705-11.
22. Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop. 2004;24:97-101.
23. Tokic V, Barisic I, Huzjak N, Petkovic G, Fumic K, Paschke E. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr. 2007;166:727-32.
24. Lee V, Li CK, Shing MM, Chik KW, Lam CW, Tsang KS, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant. 2000;26:455-8.